Delivering Safe and Effective Blood Products for Patients

Cerus Final Intercept United States 3


CONCORD, Calif. & DAVENPORT, Iowa--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that the Mississippi Valley Regional Blood Center (MVRBC) has signed a three-year purchase agreement for the INTERCEPT Blood System for platelets and plasma.

“With support from our donors, we provide world class blood and blood components to hospitals throughout our region,” said Mike Parejko, MVRBC’s Chief Executive Officer. “We do so with an unwavering focus on the quality and safety of our products. INTERCEPT-treated platelets and plasma will enable us to offer another safe choice of blood components to the hospitals we serve.”

The Mississippi Valley Regional Blood Center is the exclusive provider of blood products and services to 88 hospitals in Illinois, Iowa, Missouri, and Wisconsin. MVRBC is headquartered in Davenport, Iowa, where its testing, processing, and primary distribution center handles more than 400,000 units of blood components annually. The population of MVRBC’s service region exceeds 4 million residents, and donors give more than 200,000 donations each year.



Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus Corporation
Stacey Leanos - Associate Director, Investor & Public Relations
Lainie Corten - Vice President, Global Marketing & Investor Relations
925-288-6137 / This email address is being protected from spambots. You need JavaScript enabled to view it.

Mississippi Valley Regional Blood Center
Kirby Winn, Director of Public Relations
563-359-5401 / This email address is being protected from spambots. You need JavaScript enabled to view it.

Growing Adoption of Pathogen Reduction in the US